Nektar Therapeutics (NKTR)
42.26
+0.36
(+0.85%)
USD |
NASDAQ |
Dec 31, 16:00
42.26
0.00 (0.00%)
After-Hours: 20:00
Nektar Therapeutics Cash from Investing (Quarterly): -94.87M for Sept. 30, 2025
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Insmed, Inc. | -762.23M |
| Lyell Immunopharma, Inc. | 3.349M |
| Owlet, Inc. | -0.255M |
| Amgen, Inc. | -414.00M |
| Rigel Pharmaceuticals, Inc. | -33.18M |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | -48.76M |
| Cash from Financing (Quarterly) | 141.68M |
| Free Cash Flow | -190.35M |
| Free Cash Flow Per Share (Quarterly) | -2.580 |
| Free Cash Flow to Equity (Quarterly) | -39.22M |
| Free Cash Flow to Firm (Quarterly) | -42.83M |
| Free Cash Flow Yield | -6.98% |